Regorafenib Adjusted Dose for Chilean Patients With Chemoresistant Metastatic Colorectal Cancer: A Case Series

ecancermedicalscience - United Kingdom
doi 10.3332/ecancer.2018.875
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ecancer Global Foundation

Related search

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2019English

Atypical Metastatic Presentations in Colorectal Cancer: A Case Series

Clinical Colorectal Cancer
OncologyGastroenterology
2014English

A Systematic Review and Meta-Analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer

Anticancer Research
MedicineCancer ResearchOncology
2017English

Real‐World Adherence in Patients With Metastatic Colorectal Cancer Treated With Trifluridine Plus Tipiracil or Regorafenib

Oncologist
Cancer ResearchMedicineOncology
2019English

Response to Regorafenib at an Initial Dose of 120 Mg as Salvage Therapy for Metastatic Colorectal Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2017English

Angiogenesis Genotyping and Clinical Outcome During Regorafenib Treatment in Metastatic Colorectal Cancer Patients

Scientific Reports
Multidisciplinary
2016English

KDR Gene as a Predictive Biomarker of Response to Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC)

Journal of Pharmacogenomics & Pharmacoproteomics
2017English

Regorafenib Okayed for Colorectal Cancer

Cancer Discovery
Oncology
2012English

Regorafenib in Combination With Silybin as a Novel Potential Strategy for the Treatment of Metastatic Colorectal Cancer

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy